Last reviewed · How we verify
Raltegravir and truvada
This combination uses raltegravir to block HIV integrase and truvada (emtricitabine/tenofovir) to inhibit reverse transcriptase, together suppressing HIV replication through dual antiretroviral action.
This combination uses raltegravir to block HIV integrase and truvada (emtricitabine/tenofovir) to inhibit reverse transcriptase, together suppressing HIV replication through dual antiretroviral action. Used for HIV-1 infection treatment, HIV-1 pre-exposure prophylaxis (PrEP).
At a glance
| Generic name | Raltegravir and truvada |
|---|---|
| Also known as | Truvada is tenofovir 300 mg and emtricitabine 200 mg |
| Sponsor | The University of Texas Health Science Center, Houston |
| Drug class | Antiretroviral combination (INSTI + NRTI) |
| Target | HIV integrase; HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Raltegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV from integrating its genetic material into host cell DNA. Truvada is a nucleoside reverse transcriptase inhibitor (NRTI) combination that blocks the enzyme HIV uses to convert its RNA genome into DNA. Together, they provide complementary mechanisms to reduce viral load and prevent disease progression.
Approved indications
- HIV-1 infection treatment
- HIV-1 pre-exposure prophylaxis (PrEP)
Common side effects
- Nausea
- Diarrhea
- Headache
- Renal impairment (tenofovir-related)
- Bone density loss
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Post-Exposure Prophylaxis in Health Care Workers (PHASE4)
- Research on the Psychological Status of Patients With HIV-1 Infection
- Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (PHASE2, PHASE3)
- A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: